EVOK Evoke Pharma, Inc. Stock Quote

EVOK [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-2.98	Insider Own	2.46%	Shs Outstand	32.66M	Perf Week	12.11%
Market Cap	10.34M	Forward P/E	-	EPS next Y	-2.88	Insider Trans	0.00%	Shs Float	31.93M	Perf Month	20.45%
Income	-8.10M	PEG	-	EPS next Q	-0.60	Inst Own	5.00%	Short Float	0.19%	Perf Quarter	-46.48%
Sales	1.90M	P/S	5.44	EPS this Y	48.60%	Inst Trans	-2.45%	Short Ratio	0.05	Perf Half Y	-50.95%
Book/sh	0.71	P/B	4.56	EPS next Y	-9.10%	ROA	-66.40%	Target Price	78.00	Perf Year	-80.29%
Cash/sh	2.41	P/C	1.34	EPS next 5Y	40.00%	ROE	-199.80%	52W Range	2.03 - 18.96	Perf YTD	-50.91%
Dividend	-	P/FCF	-	EPS past 5Y	25.40%	ROI	-94.80%	52W High	-83.02%	Beta	0.68
Dividend %	-	Quick Ratio	6.40	Sales past 5Y	-	Gross Margin	85.30%	52W Low	58.62%	ATR	0.37
Employees	4	Current Ratio	6.70	Sales Q/Q	300.00%	Oper. Margin	-	RSI (14)	52.14	Volatility	9.40% 11.26%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	20.70%	Profit Margin	-	Rel Volume	0.02	Prev Close	3.24
Shortable	No	LT Debt/Eq	2.63	Earnings	May 10 AMC	Payout	-	Avg Volume	1.26M	Price	3.22
Recom	2.00	SMA20	16.62%	SMA50	-14.50%	SMA200	-59.32%	Volume	31,073	Change	-0.62%

Jun-22-20

Upgrade

H.C. Wainwright

Neutral → Buy

$10

Mar-05-19

Downgrade

H.C. Wainwright

Buy → Neutral

Mar-08-18

Reiterated

B. Riley FBR, Inc.

Buy

$10 → $5

Oct-19-17

Resumed

FBR & Co.

Buy

$10

Mar-16-17

Reiterated

Rodman & Renshaw

Buy

$6 → $9

Jan-30-17

Upgrade

Laidlaw

Neutral → Buy

Jan-05-17

Upgrade

Rodman & Renshaw

Neutral → Buy

$2.50 → $6

Dec-23-16

Reiterated

Rodman & Renshaw

Neutral

$2 → $2.50

Jul-19-16

Reiterated

FBR Capital

Outperform

$17 → $9

Jul-19-16

Downgrade

Noble Financial

Buy → Hold

Jul-18-16

Downgrade

Rodman & Renshaw

Buy → Neutral

Mar-16-16

Initiated

Northland Capital

Outperform

Mar-14-16

Reiterated

Ascendiant Capital Markets

Buy

$11 → $12

Feb-17-16

Resumed

FBR Capital

Outperform

$17

Dec-03-14

Reiterated

MLV & Co

Buy

$12.50 → $14

Nov-07-14

Initiated

MLV & Co

Buy

$12.50

Apr-22-14

Initiated

Laidlaw

Buy

$19

Nov-19-13

Initiated

Aegis Capital

Buy

$60

Jun-15-22 08:30AM	Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program GlobeNewswire +47.06%
Jun-08-22 08:30AM	Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update GlobeNewswire
May-23-22 07:00AM	Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported GlobeNewswire -11.53%
May-18-22 08:30AM	Patient Experience Survey Reported Positive Findings for GIMOTI® GlobeNewswire -7.99%
May-17-22 08:30AM	Evoke Pharma to Present at H.C. Wainwright Global Investment Conference GlobeNewswire +5.42%
May-10-22 04:05PM	Evoke Pharma Reports First Quarter 2022 Financial Results GlobeNewswire -7.90%
May-03-22 08:30AM	Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022 GlobeNewswire -6.21%
Apr-26-22 11:36AM	Warner Bros. Discovery adds 2 million subscribers in first earnings report Yahoo Finance Video +118.50%
08:54AM	Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray Benzinga
08:30AM	Evoke Pharma Granted FDA Market Exclusivity for GIMOTI® GlobeNewswire
Apr-19-22 08:30AM	Evoke Pharma Announces Approval of GIMOTI® to the Texas Medicaid Preferred Drug List GlobeNewswire +14.73%
Mar-10-22 08:30AM	Evoke Pharma Announces Key Opinion Leader Fireside Chat to Discuss Gastroparesis Treatment Landscape GlobeNewswire
Mar-08-22 04:05PM	Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Mar-01-22 08:30AM	Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022 GlobeNewswire -7.14%
Feb-24-22 08:30AM	Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease Week (DDW) May 2022 GlobeNewswire
Feb-17-22 08:30AM	GIMOTI® Commercialization Update GlobeNewswire
Feb-02-22 08:30AM	Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI GlobeNewswire
Jan-04-22 08:30AM	Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference GlobeNewswire -5.57%
Nov-10-21 04:05PM	Evoke Pharma Reports Third Quarter 2021 Financial Results GlobeNewswire -6.92%
Nov-03-21 08:30AM	Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021 GlobeNewswire
Oct-20-21 08:30AM	Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research Study GlobeNewswire
Sep-29-21 08:30AM	Evoke Pharmas Commercial Partner EVERSANA, Receives PM360s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTI GlobeNewswire -6.11%
Sep-10-21 07:53AM	Evoke Pharma (NASDAQ:EVOK) Has Debt But No Earnings; Should You Worry? Simply Wall St. +5.61%
Sep-01-21 08:30AM	Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-16-21 07:20AM	24 Stocks Moving in Monday's Pre-Market Session Benzinga
Aug-12-21 04:05PM	Evoke Pharma Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-05-21 08:30AM	Evoke Pharma to Report Second Quarter 2021 Financial Results on August 12, 2021 GlobeNewswire
Aug-02-21 08:30AM	Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders (IFFGD) August Gastroparesis Awareness Month GlobeNewswire
Jul-14-21 08:30AM	Evoke Pharma Launches Gimoti® Patient and Physician Experience Program GlobeNewswire
Jun-29-21 08:30AM	Evoke Pharma, EVERSANA and The International Foundation for Gastrointestinal Disorders Announce Membership into IFFGDs Industry Council GlobeNewswire -8.22%
Jun-15-21 08:30AM	Evoke Pharma and EVERSANA Announce Positive Findings from Second GIMOTI® Market Research Study GlobeNewswire
Jun-08-21 08:30AM	Evoke Pharma Announces FDA Orange Book Listing of U.S. Patent for Gimoti® GlobeNewswire +5.34%
Jun-02-21 08:30AM	Evoke Pharma Announces Issuance of a New U.S. Patent Covering Methods of Use for Gimoti® GlobeNewswire -5.15%
May-27-21 08:30AM	Evoke Pharma and EVERSANA Launch Social Media Campaign for Gimoti® Nasal Spray GlobeNewswire
May-14-21 08:30AM	Evoke Pharma Appoints Vickie Reed to Board of Directors GlobeNewswire
May-12-21 04:05PM	Evoke Pharma Reports First Quarter 2021 Financial Results GlobeNewswire
02:30PM	Evoke Pharma, Inc. to Host Earnings Call ACCESSWIRE
May-05-21 08:30AM	Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021 GlobeNewswire
Apr-06-21 08:30AM	Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti® GlobeNewswire +5.29%
Mar-30-21 08:30AM	Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis GlobeNewswire
Mar-14-21 04:52AM	Evoke Pharma, Inc. (NASDAQ:EVOK) Is Expected To Breakeven In The Near Future Simply Wall St.
Mar-11-21 06:05PM	Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates Zacks +6.90%
04:05PM	Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
02:30PM	Evoke Pharma, Inc. to Host Earnings Call ACCESSWIRE
Mar-04-21 04:05PM	Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021 GlobeNewswire -6.57%
Jan-20-21 08:30AM	Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-13-21 08:03PM	Evoke Pharma Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:02PM	Evoke Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire
08:30AM	Evoke Pharma Announces Positive Findings from GIMOTI Market Research Study GlobeNewswire
Dec-17-20 08:55AM	Do Options Traders Know Something About Evoke Pharma (EVOK) Stock We Don't? Zacks +13.33%
Nov-10-20 08:30AM	Evoke Pharma Reports Third Quarter 2020 Financial Results GlobeNewswire
Oct-26-20 08:30AM	Evoke and EVERSANA Announce Commercial Launch of Gimoti GlobeNewswire
Sep-09-20 08:30AM	Evoke Pharma to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Aug-25-20 08:30AM	Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti GlobeNewswire
Aug-24-20 07:27AM	New Strong Sell Stocks for August 24th Zacks
Aug-06-20 08:30AM	Evoke Pharma Reports Second Quarter 2020 Financial Results GlobeNewswire
Jul-15-20 08:30AM	Evoke Pharma Initiates Commercial Manufacturing of Gimoti GlobeNewswire
Jul-08-20 08:30AM	Evoke Pharma Extends Cash Runway to 2Q 2021 GlobeNewswire
Jun-25-20 10:58PM	Evoke Pharma Set to Gain 170%? This 5-Star Analyst Thinks So SmarterAnalyst +6.57%
Jun-22-20 10:23AM	Price Over Earnings Overview: Evoke Pharma Benzinga +61.70%
Jun-19-20 03:32PM	FDA Approves Evokes GIMOTI GlobeNewswire
May-20-20 08:30AM	Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission GlobeNewswire +14.86%
May-12-20 08:30AM	Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format GlobeNewswire
Mar-12-20 08:30AM	Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire -18.02%
Jan-27-20 08:30AM	Evoke Pharma Receives Notice of Allowance from USPTO for Gimoti GlobeNewswire
Jan-23-20 08:30AM	Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti GlobeNewswire +5.48%
Jan-22-20 10:00AM	Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance Zacks
Jan-21-20 08:30AM	FDA Accepts Evoke Pharmas NDA Resubmission for Gimoti GlobeNewswire
Dec-20-19 08:30AM	Evoke Resubmits Gimoti New Drug Application to FDA GlobeNewswire
Dec-02-19 08:30AM	Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement GlobeNewswire
Nov-18-19 08:52AM	What Kind Of Shareholder Appears On The Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shareholder Register? Simply Wall St. +34.55%
Nov-13-19 08:30AM	Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price GlobeNewswire
Nov-07-19 08:30AM	Evoke Pharma Reports Third Quarter 2019 Financial Results GlobeNewswire
Sep-20-19 05:14PM	Foamix Initiates Phase II Study on Acne Combination Foam Zacks
Sep-19-19 12:02PM	When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Come Back To Market? Simply Wall St.
10:29AM	Zynerba Releases Data on Epilepsy Candidate, Stock Down Zacks
Sep-17-19 08:30AM	Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti GlobeNewswire
Aug-08-19 05:30AM	Evoke Pharma to Resubmit Gimoti NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 12:58PM	Biotech Stock On The Radar: Evoke Pharma Sets Date With FDA Benzinga
Jul-11-19 11:31AM	Is Evoke Pharma, Inc. (NASDAQ:EVOK) A Volatile Stock? Simply Wall St.
Jun-27-19 08:30AM	Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti NDA GlobeNewswire
May-08-19 04:05PM	Evoke Pharma Reports First Quarter 2019 Financial Results GlobeNewswire
11:39AM	Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store? Zacks
Apr-29-19 09:13AM	Investors Who Bought Evoke Pharma (NASDAQ:EVOK) Shares Five Years Ago Are Now Down 92% Simply Wall St.
Apr-15-19 12:08PM	Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs Zacks
Apr-03-19 08:19AM	The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
Apr-02-19 06:00AM	Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti NDA GlobeNewswire
Mar-29-19 12:45PM	Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates Benzinga
Mar-14-19 08:30AM	Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA GlobeNewswire
Mar-06-19 08:30AM	Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication GlobeNewswire
Mar-04-19 08:30AM	Evoke Pharma Receives Preliminary FDA Communication on Gimoti NDA GlobeNewswire
Feb-27-19 08:30AM	Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Jan-07-19 08:30AM	Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti in the U.S. with Novos Growth Partners GlobeNewswire
Jan-04-19 07:56AM	Loss-Making Evoke Pharma, Inc. (NASDAQ:EVOK) Expected To Breakeven Simply Wall St.
Nov-13-18 04:05PM	Evoke Pharma Reports Third Quarter 2018 Results GlobeNewswire
Oct-16-18 10:32AM	Shareholders Should Check The Ownership Structure Of Evoke Pharma Inc (NASDAQ:EVOK) Simply Wall St.
Oct-08-18 06:28PM	Generic-Drugs Stock Outlook: No Respite from Pricing Issues Zacks
Sep-28-18 09:59AM	Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead Zacks
Aug-17-18 09:12AM	Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA Zacks
Aug-16-18 08:30AM	Evoke Pharmas Gimoti NDA Accepted for FDA Review GlobeNewswire

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience